MARKET

PTGX

PTGX

Protagonist
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.13
+0.90
+4.05%
After Hours: 23.13 0 0.00% 16:02 11/25 EST
OPEN
22.51
PREV CLOSE
22.23
HIGH
23.61
LOW
22.05
VOLUME
157.51K
TURNOVER
--
52 WEEK HIGH
24.02
52 WEEK LOW
4.470
MARKET CAP
884.88M
P/E (TTM)
-10.7183
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Protagonist Therapeutics to Present at the Virtual Piper Sandler 32nd Annual Healthcare Conference
PR Newswire · 1d ago
Protagonist Therapeutics Q3 EPS $(0.21) Up From $(0.61) YoY, Sales $13.11M Up From $4.14M YoY
Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly losses of $(0.21) per share. This is a 65.57 percent increase over losses of $(0.61) per share from the same period last year. The company reported $13.11
Benzinga · 11/04 22:09
Protagonist EPS beats by $0.40, beats on revenue
Protagonist (PTGX): Q3 GAAP EPS of -$0.21 beats by $0.40.Revenue of $13.11M (+216.7% Y/Y) beats by $10.96M.Press Release
Seekingalpha · 11/04 22:06
Protagonist Therapeutics, Janssen advance oral IL-23 receptor antagonists program
Protagonist Therapeutics' (PTGX) two additional oral peptide IL-23 receptor antagonist candidates - PN-235 (JNJ-77242113) and PN-232 (JNJ-75105186) from its collaboration agreement with Johnson & Johnson (JNJ) unit, Janssen Biotech, have been selected for advancement
Seekingalpha · 10/30 10:44
Protagonist Therapeutics Announces Two Additional Oral IL-23 Receptor Antagonists From Program In Collaboration With Janssen Have Been Selected For Advancement Into Clinical Development
NEWARK, Calif., Oct. 29, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that two additional oral peptide IL-23 receptor antagonist candidates from its collaboration agreement with
Benzinga · 10/29 21:14
Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that two additional oral peptide IL-23 receptor antagonist candidates from its collaboration agreement with Janssen Biotech, Inc., have been selected for advancement into clinical development. The two new candidates, PN-235 (JNJ-77242113) and PN-232 (JNJ-75105186), are being developed as part of a portfolio strategy of discovering and developing oral IL-23 receptor antagonists. The initial oral candidate in the collaboration agreement, PTG-200 (JNJ-67864238), is currently in a Phase 2 proof-of-concept study in patients with moderate to severe Crohn's disease.
PR Newswire · 10/29 20:30
Protagonist Therapeutics's lead asset an Orphan Drug in Europe for a type of blood cancer
The European Medicines Agency has designated Orphan Drug status to Protagonist Therapeutics's (PTGX) PTG-300 for the treatment of polycythemia vera, a type of blood cancer in which the bone marrow produces too
Seekingalpha · 10/21 11:21
Here's What We Think About Protagonist Therapeutics' (NASDAQ:PTGX) CEO Pay
Dinesh Patel has been the CEO of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) since 2008, and this article will...
Simply Wall St. · 10/09 16:53
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PTGX. Analyze the recent business situations of Protagonist through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PTGX stock price target is 31.75 with a high estimate of 37.00 and a low estimate of 27.00.
EPS
Institutional Holdings
Institutions: 141
Institutional Holdings: 41.64M
% Owned: 108.86%
Shares Outstanding: 38.26M
TypeInstitutionsShares
Increased
30
2.62M
New
30
2.10M
Decreased
32
1.84M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.74%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/Independent Director
Harold Selick
President/Chief Executive Officer/Director
Dinesh Patel
Chief Financial Officer/Chief Accounting Officer
Donald Kalkofen
Chief Scientific Officer
David Liu
Other
Suneel Gupta
Other
Samuel Saks
Independent Director
Bryan Giraudo
Independent Director
Sarah Noonberg
Independent Director
Sarah O'Dowd
Independent Director
William Waddill
Independent Director
Lewis Williams
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PTGX
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Protagonist Therapeutics Inc stock information, including NASDAQ:PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.